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ABSTRACT
Objectives: To determine the role of baseline ultrasound findings and the changes between β- human chorionic gonadotro-
pin (hCG) values on day 0 to day 4 in patients receiving single-dose methotrexate (MTX) therapy for tubal ectopic pregnancy.
Material and methods: One hundred fourteen patients who were hospitalized with a diagnosis of ectopic pregnancy and 
treated with single-dose methotrexate were included in this retrospective study. The successful treatment group (n = 88) 
comprised patients in whom serum β-hCG levels were resolved with single-dose methotrexate treatment, and the failed 
treatment group (n = 26) included patients who received second dose methotrexate and/or surgery. Ultrasound findings, 
laboratory findings, and serum β-hCG values at the time of admission and D4 and D7 β-hCG values were compared.
Results: The success rate of single-dose methotrexate treatment was 77.2%. In the successful treatment group, the initial 
β-hCG values of the patients were lower than the unsuccessful treatment group (1479.14 ± 1253.49, 4442.88 ± 3392.58, 
respectively) (p = 0.0001). A decrease of more than 35% between D0-D4 increased the probability of successful treatment 
(p = 0.017). Although ectopic focus size and abdominal free fluid showed no significant difference between the two groups, 
endometrial stripe thickness was significantly higher in the unsuccessful treatment group (12.61 ± 5.79, 9.28 ± 3.53) (p = 0.002).
Conclusions: In addition to the basal β-hCG value, endometrial stripe thickness of ultrasound findings should also be 
considered in determining patients with a high chance of success in single-dose MTX treatment.β-hCG changes between 
D0-D4 may be advantageous in the clinical management of ectopic pregnancy for earlier evaluation.
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INTRODUCTION
Ectopic pregnancy (EP) is a condition in which the de-
veloping blastocyst is implanted in a tissue other than the 
uterine cavity endometrium, most commonly in the fal-
lopian tube (98%) [1]. The incidence of ectopic pregnancy, 
which can cause severe maternal morbidity and mortality, 
is around 2% [2]. However, its frequency increases with each 
passing day due to increasing assisted reproductive tech-
nology (ART) applications and increasing pelvic inflamma-
tory disease (PID) [3]. Nowadays, serial β-human chorionic 
gonadotropin (hCG) measurements and high-resolution 
ultrasound can be used for early diagnosis. Early diagnosis 
and treatment reduce maternal mortality, protects from 
tubal rupture, and allows fertility to be maintained.
Methotrexate (MTX), a folate antagonist, shows anti-mi-
totic activity in tissues with high proliferative capacity such 
as chorionic villi [4]. Medical treatment is a good alternative 
to surgery because it is effective, safe, and economical [5]. 
It was first reported by Tanaca et al. [6] that MTX was used 
successfully in the treatment of ectopic pregnancy in 
1982. Single-dose, fixed multi-dose, and variable multi-dose 
regimens have been defined for MTX applications [7]. The 
most preferred single-dose protocol was developed by 
Stovall et al. [8] in 1991. Success in the single-dose protocol 
was defined as a decrease in β-hCG of > 15% between days 
4 and 7 of MTX administration. The positive predictive value 
reaches 93% [9]. However, one-week follow-up increases 
the length of hospital stay or requires patient compliance 
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for β-hCG follow-up. Also, during this time, tubal rupture 
may occur and emergency surgery may be required. Thus, 
an earlier predictive value, including baseline ultrasound 
data, to assess success may allow earlier intervention to 
those with a potential for treatment failure and make clinical 
management of ectopic pregnancy more effective.
Objectives
Evaluating the role of baseline ultrasound findings 
for determining patients with a high chance of success in 
single-dose MTX treatment. Although the cornerstone of 
MTX treatment monitoring is the change in β-hCG values 
between days 7 and 4, we are looking for an answer to the 
question of whether early prediction of the treatment suc-
cess by evaluating change in β-hCG values between days 
4 and 0 can bring a new perspective to clinical management 
of ectopic pregnancy.
MATERIAL AND METHODS
The data and patient files of patients who were hospital-
ized at our Training and Research Hospital with a diagnosis 
of ectopic pregnancy between May 2016 and December 
2018 and treated with methotrexate were retrieved from 
the hospital’s electronic registry system and retrospectively 
reviewed. Patient age, obstetric history, transvaginal ul-
trasound findings (ectopic focal size, endometrial stripe 
thickness, presence and amount of free fluid in the pouch of 
Douglas), complete blood count parameters, β-hCG values 
from days 0, 4, and 7 and following weeks, and treatment 
results were recorded.
The definitive diagnosis of ectopic pregnancy was 
made if the gestational sac and/or embryo were seen in 
the adnexal area and trophoblastic tissue was not observed 
in the uterine cavity on pathologic examination. Possible 
ectopic pregnancy diagnosis was defined as the presence 
of suspected adnexal mass or free fluid in the pouch of 
Douglas in the existence of abnormally increased or plateau 
β-hCG values or β-hCG values > 1500–2000 IU/L, with no 
intrauterine pregnancy observed on transvaginal ultrasound 
(TVUSG). These patients were candidates for methotrexate 
treatment in the absence of any contraindications to medi-
cal treatment; hemodynamic instability, acute abdominal 
findings, abnormal hematologic, renal, hepatic laboratory 
values, acute pulmonary disease, active peptic ulcer and 
breastfeeding mother. 
While deciding on medical treatment/surgical treat-
ment in our clinic, the patient’s hemodynamic status, de-
sire for fertility, ectopic focus size, serum β-hCG value, fetal 
heartbeat positivity, and compliance of the patient with 
the treatment process are considered. A single-dose MTX 
treatment protocol is applied to patients who are eligible as 
recommended in the American College of Obstetricians and 
Gynecologists Application Bulletin [10]. Day 0: β-hCG value, 
whole blood count, blood group, renal and hepatic function 
tests and lung radiography are evaluated in patients with 
a history of lung disease. Day 1: 50 mg/m2 body surface 
area, intramuscular MTX is applied. Day 4: β-hCG, and day 7: 
complete blood count and β-hCG are examined. Success-
ful treatment with single-dose MTX is a > 15% reduction in 
β-hCG between days 7 and 4, and a decrease in β-hCG of 
less than < 5 IU/L during weekly β-hCG follow-ups. Failure of 
single-dose MTX treatment was considered as the require-
ment for a repeated MTX dose due to a decrease in β-hCG 
values of days 7 and 4 < 15%, or surgical treatment of tubal 
rupture due to hemodynamic instability at any stage of 
treatment.
The study was started after receiving approval from 
the local ethics committee. The patients were divided into 
two groups according to the results of single-dose MTX 
treatment. Age, gravida, parity, laboratory findings, TVUSG 
findings, and β-hCG values at the start, 4th and 7th days were 
compared retrospectively between the groups.
Data were analyzed using the IBM SPSS Statistics 18© 
(SPSS Inc., 1989 2010) software package. The compatibility of 
continuous variables with normal distribution was examined 
using the Kolmogorov-Smirnov test. The categorical varia-
bles in the study are presented as frequency and percentage, 
and continuous variables as mean and standard deviation 
values. Chi-square and Fisher’s Chi-square tests were used 
to analyze categorical variables. Since the independent 
comparisons of two groups did not meet the parametric 
test assumptions, the Mann-Whitney U test for independ-
ent measures of two group, and dependent groups were 
analyzed using the Friedman test. Furthermore, the pos-
sible factors determined by univariate analyzes were then 
analyzed by a multiple logistic regression model. The level 
of statistical significance was accepted as 0.05.
RESULTS
In this retrospective cohort study, the data of 304 pa-
tients admitted to our clinic with a diagnosis of ectopic 
pregnancy between May 2016 and December 2018 were 
reviewed; 21 patients were excluded from the study due to 
insufficient data or refusal of treatment. Expectant manage-
ment was applied to 16 patients, spontaneous resolution 
was observed, and no additional treatment was required 
during the follow-up. One hundred fifty-three patients un-
derwent primary surgical treatment.
Single-dose MTX was administered to 114 patients, 
88 patients were treated successfully, and the success rate 
was 77.2%. Of the 26 patients who failed single-dose MTX 
treatment; 14 patients received a second dose of MTX, 10 pa-
tients underwent surgical treatment, and 2 patients had 
surgical treatment after a second dose of MTX.
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The demographic data, and ultrasound and laboratory find-
ings of the groups were divided according to MTX treatment 
success/failure (Tab. 1). Among the groups, there was no differ-
ence in terms of age (31.76 ± 5.77 vs 30.35 ± 5.66 years), gravida 
(2.84 ± 1.48 vs 2.46 ± 1.30), and parity (1.41 ± 1.09 vs 1.00 ± 0.89). 
Initial β-hCG values were found as 1479.14 ± 1253.49 in the 
successful treatment group and 4442.88 ± 3392.58 in the 
failed treatment group, which was statistically significantly 
different (p = 0.0001). β-hCG values at day 0, day 4, and day 
7 were statistically lower in the successful treatment group 
than in the unsuccessful treatment group. Ectopic focal size 
showed no significant difference between the two groups 
(20.65 ± 10.48, 19.40 ± 5.95, respectively); however, endome-
trial stripe thickness was significantly higher in the unsuccess-
ful treatment group (12.61 ± 5.79 vs 9.28 ± 3.53) (p = 0.002).
There was no correlation between the presence and 
amount of free fluid in the abdomen and the success or 
failure of treatment (Tab. 2).
In a multivariate logistic regression analysis, only two 
independent determinants; day 4 β-hCG values and day 
7 β-hCG values were significantly associated with treatment 
success (Tab. 3).
The overall success rate of MTX treatment was 77.2%. 
The success rate was found as 87.5% for those with β-hCG 
values falling between D0-D4, and 59.5% in those whose 
values rose in the same period (Tab. 4).
A decrease of more than 35% between D0-D4 increases 
the probability of successful treatment (p = 0.017). Between 
D0–D4, 97.1% of those with a reduction of more than 35% 
had successful treatment (Tab. 5).
DISCUSSION
Despite the advances in diagnostic and treatment meth-
ods, EP, which causes 6–13% of pregnancy-related deaths, is 
still an important cause of first trimester maternal deaths [1, 11]. 
Medical treatment with MTX is a good alternative to surgery 
Table 1. Demographic data, and laboratory and ultrasonography data
Successful  
(n = 88)
Unsuccessful  
(n = 26) p value
Age 31.76 ± 5.77 30.35 ± 5.66 0.241
Gravida 2.84 ± 1.48 2.46 ± 1.30 0.288
Parity 1.41 ± 1.09 1.00 ± 0.89 0.131
Endometrial 
Thickness [mm] 9.28 ± 3.53 12.61 ± 5.79 0.002
Ectopic focus 
size [mm] 20.65 ± 10.48 19.40 ± 5.95 0.066
Hb 11.75 ± 1.38 11.87 ± 1.08 0.663
Plt 246.35 ± 82.69 253.67 ± 71.71 0.968
WBC 7.99 ± 2.49 8.02 ± 1.74 0.844
Neutrophils 7.94 ± 1.70 4.93 ± 1.54 0.891
Lymphocytes 2.02 ± 0.64 2.19 ± 0.40 0.584
β-hCG Day 0 1479.14 ± 1253.49 4442.88 ± 3392.58 0.0001
β-hCG Day 4 1133.81 ± 1044.38 5315.92 ± 4153.30 0.0001
β-hCG Day 7 609.59 ± 652.20 4779.96 ± 3525.71 0.0001
*Mann-Whitney U Test; Hb — Hemoglobin; Plt — Platelet count;  
WBC — White Blood Cell 
Table 2. The relationship between the presence of free fluid in the 
abdomen and treatment success
Successful 
n (%)
Unsuccessful 
n (%) Total n (%) p value
Free liquid in the abdomen
None 71 (77.2%) 21 (22.8%) 92 (100.0%)
0.149Minimal 16 (84.2%) 3 (15.8%) 19 (100.0%)
Plentiful 1 (33.3%) 2 (66.7%) 3 (100.0%)
Minimal — < 3 cm free fluid; Plentiful — > 3 cm free fluid
Table 3. Multivariate logistic regression analysis of the factors 
associated with treatment success
Variable OR 95% CI p
Endometrial Thickness 1.211 0.942–1.557 0.135
β-hCG Day 0 0.999 0.998–1.000 0.220
β-hCG Day 4 0.996 0.993–1.000 0.027
β-hCG Day 7 1.008 1.003–1.012 0.001
*Nagelkerle R Square: 0.838; OR — Odds Ratio; CI — confidence interval
Table 4. Relationship between β-hCG 0-4 days change values and 
success rate
Successful 
n (%)
Unsuccessful 
n (%) Total n (%) p value
Falling 63 (87.5%) 9 (12.5%) 72 (100.0%)
0.001Rising 25 (59.5%) 17 (40.5%) 42 (100.0%)
Total 88 (77.2%) 26 (22.8%) 114 (100.0%)
*Chi-square test
Table 5. Effect of β-hCG change rates between D0-D4 on treatment 
success
Successful 
n (%)
Unsuccessful 
n (%) Total n (%) p value
Decrease  between D0-D4
≤ 35% 29 (78.4%) 8 (21.6%) 37 (100.0%)
0.017
> 35% 34 (97.1%) 1 (2.9%) 35 (100.0%)
Total 63 (87.3%) 9 (12.7%) 72 (100.0%)
Increase between D0–D4
≤ 18% 14 (66.7%) 7 (33.3%) 21 (100.0%)
0.346
≥ 18% 11 (52.4%) 10 (47.6%) 21 (100.0%)
Total 25 (59.5%) 17 (40.5%) 42 (100.0%)
* Chi-square and Fisher Chi-square test
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because it is economical, effective, and non-invasive, but 
may not always be the best treatment option. Hemodynamic 
stability, the absence of fetal heartbeat, and absence of tubal 
rupture findings, which are accepted as indication for MTX 
treatment by most authors, but patient selection remains 
controversial with regard to the presence of abdominal 
free fluid and ectopic focus size [7, 10]. Some authors state 
that the ectopic focal size should be < 3.5 cm [10]. Kimiaei 
et al. [12] reported that in addition to initial β-hCG, ectopic 
focus size was also significant in evaluating treatment suc-
cess. There are also studies reporting that ectopic focal size 
has no effect on treatment outcome [13, 14].
Gnıscı et al. [15] reported that hemoperitoneum was 
strongly associated with treatment failure and was more 
valuable than ectopic focal size and initial β-hCG value in 
predicting failure, but still found that MTX treatment was 
successful in more than half of all patients with hemoperi-
toneum. Lipscomb et al. [16] reported that free peritoneal 
fluid detection on ultrasound posed no risk for treatment 
failure in their study of 350 patients treated with MTX. The 
presence of free fluid in the abdomen may also be physi-
ological [17]. Sargin et al. [18] stated that the first choice in 
treatment was medical treatment with expectant manage-
ment or MTX, even if there was free fluid in the abdomen at 
the initial evaluation in a hemodynamically stable patient.
In our study, neither ectopic focus size nor the presence 
of free fluid in the abdomen was found to be associated 
with treatment failure. However, endometrial thickness was 
found to be significantly higher in the group with unsuccess-
ful treatment (12.61 ± 5.79 mm) than in the successful MTX 
treatment group (9.28 ± 3.53 mm) (p = 0.002). Similarly, in 
a study where MTX treatment was successful, the mean en-
dometrial thickness was 6.4 mm and the β-hCG value was 
1936.2 mIU/mL, whereas in the group that failed, endome-
trial  thickness was 11.7 mm and the mean β-hCG was found 
as 6831.3 mIU/mL [19].  In another study, it was reported that 
the rate of treatment failure with MTX increased if endome-
trial thickness > 12 mm [20]. Endometrial thickness was said 
to reflect the serum β-hCG level of the patient.
Soares et al. [21] reported that fast rising β-hCG values 
before treatment, as another predictive variable in the selec-
tion of patients for medical treatment of ectopic pregnancy 
with MTX, were effective in predicting treatment failure. In 
previous studies, baseline β-hCG is the most recommended 
parameter for successful treatment prediction. In the litera-
ture, close β-hCG thresholds for MTX treatment success have 
been reported. Rabischong et al. [22] found this value as 
1300 IU/L, Markwitz et al. [23] reported 1790 IU/L, Pulatoglu 
et al. [24] found 1362 IU/L, and Corsan et al. [25] reported 
1500 IU/L. In the current study contrary to expectations 
initial β-hCG value was not found to be an independent fac-
tor for the treatment outcome, similar with Levin at al. [26] 
Large range (72–12660) of the initial β-hCG values; including 
patients with a higher β-hCG concentration above the upper 
concentration limit allowed for single-dose regimen in the 
American College of Obstetricians and Gynecologists Appli-
cation Bulletin [10] may have been effective on this finding.
The fact that cytotrophoblasts had a doubling time of 
48 hours led investigators to evaluate earlier than 7 days to 
determine the efficacy of MTX, which inhibits cellular DNA 
synthesis by inactivating dihydrofolate reductase [27]. In 
a retrospective study of 30 patients, Nguyen et al. reported 
treatment success as 100% in patients with a decrease in 
β-hCG values on day 4, a decrease between D0–D4 was 
highly predictive, and that these patients might not need 
to be followed up on day 7, also avoiding an unnecessary 
second MTX dose [28]. Again, in a retrospective study of 
45 patients, the single-dose MTX success rate was 76%, 
and the treatment success rate was reported as 88% in 
patients with decreased D0–D4 β-hCG [29]. In a prospec-
tive study of 129 patients, Agostini et al. [30] reported that 
a > 20% reduction in D0-D4 β-hCG values was effective in 
predicting MTX success with a positive predictive value of 
97%. In a case-control study of 140 patients by Mashiach et 
al. [31], it was reported that an increase of more than 50% 
of β-hCG between D0–D4 indicated MTX treatment fail-
ure; however, it may help clinical management by giving 
an idea of MTX treatment outcomes in borderline situa-
tions rather than making a surgical decision based on this 
increase. In a recent retrospective study of 121 patients, it 
was stated that monitoring could be reduced in patients 
with a > 30% decrease in D0–D4 β-hCG values, and in pa-
tients with a > 70% increase, second-dose MTX could be 
administered [32]. Finally, Levin et al. advocated that β-hCG 
increment of less than 17% in the 24 hr pretreatment, and 
a decrease of more than 22% between day1 and day 4 β-hCG 
concentations might predict the success of single-dose 
MTX treatment [26]. In our study, the overall success rate 
was comparable to the literature with 77.2% [13, 24, 28, 29]. 
The success rate of single-dose MTX treatment for those 
whose β-hCG values fell between D0–D4 was 87.3%, and 
59.5% in those whose levels rose. Single-dose MTX treat-
ment was successful in 97% of patients with D0–D4 β-hCG 
values with a > 35% decrease. However, an increase rate 
that predicted success was not determined in patients with 
increased D0–D4 β-hCG values. A small number of success-
ful patients who had an increase in β-hCG values between 
D0-D4 might be restrictive. 
CONCLUSIONS 
Determining the most appropriate patient for MTX treat-
ment and evaluating the early changes in β-hCG values in 
the medical treatment of EP with MTX will contribute to 
cost reduction, reduce the patient’s anxiety, and provide 
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further treatment options if needed. Timely surgical inter-
vention will contribute to the preservation of the fertility 
of the patient. Large-scale prospective studies are needed 
to determine the direct effect of early changes in β-hCG on 
clinical outcomes.
REFERENCES
1. Bouyer J, Coste J, Fernandez H, et al. Sites of ectopic pregnancy: a 10 year 
population-based study of 1800 cases. Hum Reprod. 2002; 17(12): 3224–
3230, doi: 10.1093/humrep/17.12.3224, indexed in Pubmed: 12456628.
2. Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality 
surveillance--United States, 1991--1999. MMWR Surveill Summ. 2003; 
52(2): 1–8, indexed in Pubmed: 12825542.
3. Shaw JLV, Dey SK, Critchley HOD, et al. Current knowledge of the aetiol-
ogy of human tubal ectopic pregnancy. Hum Reprod Update. 2010; 16(4): 
432–444, doi: 10.1093/humupd/dmp057, indexed in Pubmed: 20071358.
4. Barnhart KT, Gosman G, Ashby R, et al. The medical management 
of ectopic pregnancy: a meta-analysis comparing “single dose” and 
“multidose” regimens. Obstet Gynecol. 2003; 101(4): 778–784, doi: 
10.1016/s0029-7844(02)03158-7, indexed in Pubmed: 12681886.
5. Glock J, Johnson J, Brumsted J. Efficacy and safety of single-dose sys-
temic methotrexate in the treatment of ectopic pregnancy. Fertility and 
Sterility. 1994; 62(4): 716–721, doi: 10.1016/s0015-0282(16)56994-5.
6. Tanaka T, Hayashi H, Kutsuzawa T, et al. Treatment of interstitial ectopic 
pregnancy with methotrexate: report of a successful case. Fertility and 
Sterility. 1982; 37(6): 851–852, doi: 10.1016/s0015-0282(16)46349-1.
7. Hajenius PJ, Mol F, Mol BWJ, et al. Interventions for tubal ectopic 
pregnancy. Cochrane Database Syst Rev. 2007(1): CD000324, doi: 
10.1002/14651858.CD000324.pub2, indexed in Pubmed: 17253448.
8. Prevost RR, Stovall TG, Ling FW, et al. Single-dose methotrexate for 
treatment of ectopic pregnancy. Obstet Gynecol. 1991; 77(5): 754–757, 
indexed in Pubmed: 2014091.
9. Kirk E, Condous G, Van Calster B, et al. A validation of the most commonly 
used protocol to predict the success of single-dose methotrexate in the 
treatment of ectopic pregnancy. Hum Reprod. 2007; 22(3): 858–863, doi: 
10.1093/humrep/del433, indexed in Pubmed: 17088266.
10. American College of Obstetricians and Gynecologists. ACOG Practice 
Bulletin No. 94: Medical management of ectopic pregnancy. Obstet Gy-
necol. 2008; 111(6): 1479–1485, doi: 10.1097/AOG.0b013e31817d201e, 
indexed in Pubmed: 18515537.
11. Cobellis G, Pierno G, Pecori E, et al. Methotrexate treatment for tubal 
pregnancy. Criteria for medical approach. Minerva Ginecol. 2003; 55(6): 
531–535, indexed in Pubmed: 14676743.
12. Kimiaei P, Khani Z, Marefian A, et al. The importance of gestational sac 
size of ectopic pregnancy in response to single-dose methotrexate. 
ISRN Obstet Gynecol. 2013; 2013: 269425, doi: 10.1155/2013/269425, 
indexed in Pubmed: 23762575.
13. Ustunyurt E, Duran M, Coskun E, et al. Role of initial and day 4 human cho-
rionic gonadotropin levels in predicting the outcome of single-dose 
methotrexate treatment in women with tubal ectopic pregnancy. Arch 
Gynecol Obstet. 2013; 288(5): 1149–1152, doi: 10.1007/s00404-013-
2879-8, indexed in Pubmed: 23666603.
14. Gunay T, Yardımcı OD, Hocaoğlu M, et al. Factors Affecting Success of 
Single-Dose Methotrexate Treatment in Ectopic Pregnancy. Kocaeli Med 
J. 2019; 8(1): 189–194.
15. Gnisci A, Stefani L, Bottin P, et al. Predictive value of hemoperitoneum 
for outcome of methotrexate treatment in ectopic pregnancy: an ob-
servational comparative study. Ultrasound Obstet Gynecol. 2014; 43(6): 
698–701, doi: 10.1002/uog.13255, indexed in Pubmed: 24265158.
16. Lipscomb GH, McCord ML, Stovall TG, et al. Predictors of success of meth-
otrexate treatment in women with tubal ectopic pregnancies. N Engl 
J Med. 1999; 341(26): 1974–1978, doi: 10.1056/NEJM199912233412604, 
indexed in Pubmed: 10607814.
17. Sickler GK, Chen PC, Dubinsky TJ, et al. Free echogenic pelvic fluid: 
correlation with hemoperitoneum. J Ultrasound Med. 1998; 17(7): 
431–435, doi: 10.7863/jum.1998.17.7.431, indexed in Pubmed: 
9669301.
18. Sargin MA, Yassa M, Taymur BD, et al. A Clinical Experience of Ectopic 
Pregnancies with Initial Free Intraperitoneal Fluid. J Clin Diagn Res. 2016; 
10(8): QC22–QC26, doi: 10.7860/JCDR/2016/20363.8376, indexed in 
Pubmed: 27656512.
19. da Costa Soares R, Elito J, Han KK, et al. Endometrial thickness as an ori-
enting factor for the medical treatment of unruptured tubal pregnancy. 
Acta Obstet Gynecol Scand. 2004; 83(3): 289–292, doi: 10.1111/j.0001-6
349.2004.0387.x, indexed in Pubmed: 14995926.
20. Takacs P, Chakhtoura N, De Santis T, et al. Evaluation of the relationship 
between endometrial thickness and failure of single-dose methotrexate 
in ectopic pregnancy. Arch Gynecol Obstet. 2005; 272(4): 269–272, doi: 
10.1007/s00404-005-0009-y, indexed in Pubmed: 16001188.
21. da Costa Soares R, Elito J, Camano L. Increment in beta-hCG in the 48-h 
period prior to treatment: a new variable predictive of therapeutic suc-
cess in the treatment of ectopic pregnancy with methotrexate. Arch 
Gynecol Obstet. 2008; 278(4): 319–324, doi: 10.1007/s00404-008-0589-4, 
indexed in Pubmed: 18274766.
22. Rabischong B, Tran X, Sleiman AA, et al. Predictive factors of failure in 
management of ectopic pregnancy with single-dose methotrexate: 
a general population-based analysis from the Auvergne Register, 
France. Fertil Steril. 2011; 95(1): 401–4, 404.e1, doi: 10.1016/j.fertns-
tert.2010.08.025, indexed in Pubmed: 20850718.
23. Nowak-Markwitz E, Michalak M, Olejnik M, et al. Cutoff value of hu-
man chorionic gonadotropin in relation to the number of methotrexate 
cycles in the successful treatment of ectopic pregnancy. Fertil Steril. 
2009; 92(4): 1203–1207, doi: 10.1016/j.fertnstert.2008.07.1775, indexed 
in Pubmed: 18851850.
24. Pulatoglu C, Dogan O, Basbug A, et al. Predictive factors of methotrexate 
treatment success in ectopic pregnancy: A single-center tertiary study. 
North Clin Istanb. 2018; 5(3): 227–231, doi: 10.14744/nci.2017.04900, 
indexed in Pubmed: 30688925.
25. Corsan GH, Karacan M, Qasim S, et al. Identification of hormonal pa-
rameters for successful systemic single-dose methotrexate therapy 
in ectopic pregnancy. Hum Reprod. 1995; 10(10): 2719–2722, doi: 
10.1093/oxfordjournals.humrep.a135774, indexed in Pubmed: 8567799.
26. Levin G, Dior U, Shushan A, et al. Early prediction of the success of metho-
trexate treatment success by 24-hour pretreatment increment in HCG 
and day 1-4 change in HCG. Reprod Biomed Online. 2019; 39(1): 149–154, 
doi: 10.1016/j.rbmo.2019.02.005, indexed in Pubmed: 31029556.
27. Rong-Hao L, Luo S, Zhuang LZ. Establishment and characterization of 
a cytotrophoblast cell line from normal placenta of human origin. Hum 
Reprod. 1996; 11(6): 1328–1333, doi: 10.1093/oxfordjournals.humrep.
a019381, indexed in Pubmed: 8671449.
28. Nguyen Q, Kapitz M, Downes K, et al. Are early human chorionic gon-
adotropin levels after methotrexate therapy a predictor of response in 
ectopic pregnancy? Am J Obstet Gynecol. 2010; 202(6): 630.e1–630.e5, 
doi: 10.1016/j.ajog.2010.03.022, indexed in Pubmed: 20510964.
29. Skubisz MM, Li J, Lee J, et al. Decline in βhCG levels between days 
0 and 4 after a single dose of methotrexate for ectopic pregnancy 
predicts treatment success: a retrospective cohort study. BJOG. 2011; 
118(13): 1665–1668, doi: 10.1111/j.1471-0528.2011.03133.x, indexed 
in Pubmed: 21895960.
30. Agostini A, Blanc K, Ronda I, et al. Prognostic value of human chori-
onic gonadotropin changes after methotrexate injection for ectopic 
pregnancy. Fertil Steril. 2007; 88(2): 504–506, doi: 10.1016/j.fertns-
tert.2006.11.138, indexed in Pubmed: 17418833.
31. Mashiach R, Kislev I, Gilboa D, et al. Significant increase in serum hCG 
levels following methotrexate therapy is associated with lower treatment 
success rates in ectopic pregnancy patients. Eur J Obstet Gynecol Reprod 
Biol. 2018; 231: 188–191, doi: 10.1016/j.ejogrb.2018.10.046, indexed in 
Pubmed: 30396108.
32. Brunello J, Guerby P, Cartoux C, et al. Can early βhCG change and baseline 
progesterone level predict treatment outcome in patients receiving 
single dose Methotrexate protocol for tubal ectopic pregnancy? Arch 
Gynecol Obstet. 2019; 299(3): 741–745, doi: 10.1007/s00404-019-05068-
1, indexed in Pubmed: 30737586.
